{"id":"metformin-rescue","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral insulin sensitivity. It may also have modest effects on glucose absorption in the intestine. The drug does not stimulate insulin secretion, making it useful across a range of glycemic states.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:00.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04029480","phase":"PHASE3","title":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT05147896","phase":"NA","title":"Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2022-05-01","conditions":"Diabetes Mellitus, Type 2, Atherosclerosis","enrollment":100},{"nctId":"NCT02947503","phase":"PHASE3","title":"Pregnancy Outcomes: Effects of Metformin Study (POEM Study)","status":"RECRUITING","sponsor":"Bethesda Diabetes Research Center","startDate":"2019-11-26","conditions":"Gestational Diabetes, Insulin Resistance","enrollment":500},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT01095653","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1179},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT00528372","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes","enrollment":1067},{"nctId":"NCT00087516","phase":"PHASE3","title":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":741},{"nctId":"NCT00757588","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes","enrollment":455},{"nctId":"NCT00374907","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes","enrollment":156},{"nctId":"NCT00316082","phase":"PHASE3","title":"Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Diabetes","enrollment":365},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306},{"nctId":"NCT00121667","phase":"PHASE3","title":"Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1462},{"nctId":"NCT00295633","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Diabetes Mellitus, Type 2","enrollment":565},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT01087567","phase":"PHASE4","title":"INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Ohio University","startDate":"2010-07","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT01206647","phase":"PHASE4","title":"Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Metformin","Glucophage","Glucophage XR","Glumetza","Fortamet"],"phase":"phase_3","status":"active","brandName":"Metformin - Rescue","genericName":"Metformin - Rescue","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin is a small molecule used to treat conditions such as type 2 diabetes and atherosclerosis, as indicated by studies on ClinicalTrials.gov. It is a medication that has been studied in combination with saxagliptin and as a monotherapy in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}